Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04391348
Overview
The objective of this protocol is to obtain a better match between the actual staging and the proposed treatment in order to avoid inadequate treatments at risk of complications. In patients with HCC classified as BCLC A to C, the combination of 18F-FDG and 18F-Fluorocholine PET- TomoDensitoMetry (TDM) with conventional imaging would clinically significantly modify the therapeutic strategy initially planned by conventional imaging alone. This change in therapeutic strategy would be from curative to palliative treatment or from loco-regional palliative to systemic palliative treatment. 18F-FDG and 18F-Fluorocholine PET-CT scans will be performed after inclusion of the patient in the study and prior to multidisciplinary consultation meeting for treatment discussion.
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
N/A
Contacts
Jean Charles NAULT, PhD (Principal Investigator)
jean-charles.nault@aphp.fr
01 48 02 41 49
Mohammed RAHAOUI
mohammed.rahaoui@aphp.fr
01 48 95 59 77
ClinicalTrials.gov
NCT04391348Drug / Compound
Help us improve your experience